“Global Cat Vaccine Market to reach a market value of USD 2.5 Billion by 2031 growing at a CAGR of 9.2%”
The Global Cat Vaccine Market size is expected to reach $2.5 billion by 2031, rising at a market growth of 9.2% CAGR during the forecast period.
The United Kingdom, Germany, and France have strict animal health regulations that require regular vaccinations, which contributes to the high compliance rates among pet owners. According to CATS REPORT 2022 published by Cats Protection, cat ownership levels vary across the UK, ranging from 24% of households in Scotland owning one or more cats to 28% of households in Wales. The growing trend of adopting stray and rescued cats, which require thorough vaccination schedules, further boosts the market in this region. Thus, the Europe region is expected to capture more than 1/4th revenue share in the market by the year 2031. A well-established veterinary care system and high levels of pet ownership support Europe's market. Additionally, the market demand is stimulated by the extensive awareness campaigns that European veterinary associations and government bodies conduct to educate pet owners about the significance of vaccinations.
The increasing prevalence of feline diseases has become a significant concern for pet owners, veterinarians, and public health officials. Among the most notable diseases are the feline leukemia virus (FeLV), feline immunodeficiency virus (FIV), and rabies, all of which pose serious threats to the health and well-being of cats. This rise in disease incidence has heightened the urgency for effective vaccination programs to prevent potential outbreaks. Veterinarians also advocate for regular vaccination schedules to safeguard cats against these prevalent diseases. Therefore, the increasing prevalence of feline diseases has raised the demand for cat vaccines.
Additionally, the rising number of households adopting cats as pets has significantly increased the demand for cat vaccines. This tendency is affected by a number of different variables, including the growing urbanization, the shifting lifestyles, and the growing realization of the mental and companionship benefits that pets provide. The International Fund for Animal Welfare estimates that China is home to 58 million domestic cats, making Asia the home of the largest population of cats in the world, which accounts for 400 million out of a total population of 600 million. Hence, the increasing number of households adopting cats as pets has increased the demand for cat vaccines.
However, the lack of knowledge can be attributed to a variety of various problems, such as a general lack of concern for the health of pets in public discourse, an inadequate number of health campaigns, and an inadequate amount of access to veterinary care at the same time. In many developing countries, veterinary services are often concentrated in urban areas, leaving rural and remote communities with minimal access to professional advice and services. Hence, the lack of awareness and education about the importance of cat vaccinations is a significant obstacle to the growth of the cat vaccine market.
Moreover, the early stages of the pandemic undoubtedly caused a strain on the veterinary healthcare system. Lockdowns and social distancing measures often led to reduced clinic hours or temporary closures. This, in turn, likely resulted in a postponement or cancellation of non-essential appointments, including routine vaccinations for cats. Moreover, research into animal vaccines for COVID-19, while still in its early stages, suggests the potential for a future market dedicated specifically to cat COVID-19 vaccines. Thus, the pandemic had an overall moderate impact on the market.
Based on duration of immunity, the market is segmented into 1 year, 3 year, and others. The 1 year segment procured 49% revenue share in the market in 2023. These vaccines are typically used for core vaccinations such as feline viral rhinotracheitis, calicivirus, and panleukopenia, which require annual boosters to maintain effective immunity. The frequency of administration ensures that cats remain protected against common and potentially severe diseases, making these vaccines a staple in routine veterinary care.
On the basis of component, the market is bifurcated into combined vaccines and mono vaccines. The combined vaccines segment recorded 62% revenue share in the market in 2023. These vaccines, which protect against multiple diseases in a single dose, are highly valued for their convenience and efficiency. By reducing the number of injections required, combined vaccines minimize the stress on cats and simplify the vaccination process for pet owners and veterinarians.
By route of administration, the market is divided into injectables, intranasal, and oral. The intranasal segment garnered 15% revenue share in the market in 2023. Intranasal vaccines are particularly effective for respiratory diseases such as feline viral rhinotracheitis and calicivirus. These vaccines offer the advantage of inducing a local immune response in the respiratory tract, providing robust protection against pathogens that enter the nasal passages.
On the basis of disease type, the market is classified into feline leukemia, feline panleukopenia (feline distemper), feline respiratory diseases, feline rabies, and others. The feline leukemia segment recorded 10% revenue share in the market in 2023. Feline leukemia virus (FeLV) is a leading cause of death in domestic cats due to its impact on the immune system and its ability to cause cancer. The serious nature of FeLV and the availability of effective vaccines have driven pet owners to prioritize vaccination against this disease.
Based on type, the market is characterized into modified/attenuated live, inactivated (killed), and others. The modified/attenuated live segment garnered 48% revenue share in the market in 2023. The modified/attenuated live vaccine segment leads the cat vaccine market due to its ability to provide strong and long-lasting immunity with fewer doses. These vaccines stimulate a robust immune response, making them highly effective against feline herpesvirus (FHV) and feline calicivirus (FCV).
Free Valuable Insights: Global Cat Vaccine Market size to reach USD 2.5 Billion by 2031
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment garnered 38% revenue share in the market in 2023. This region's dominance is driven by a high rate of pet ownership, advanced veterinary healthcare infrastructure, and strong awareness about pet health and vaccinations. In particular, the United States and Canada have robust regulatory frameworks and public health campaigns promoting regular pet vaccination schedules.
| Report Attribute | Details |
|---|---|
| Market size value in 2023 | USD 1.2 Billion |
| Market size forecast in 2031 | USD 2.5 Billion |
| Base Year | 2023 |
| Historical Period | 2020 to 2022 |
| Forecast Period | 2024 to 2031 |
| Revenue Growth Rate | CAGR of 9.2% from 2024 to 2031 |
| Number of Pages | 302 |
| Number of Tables | 539 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Porter’s 5 Forces Analysis, Company Profiling, Companies Strategic Developments, SWOT Analysis, Winning Imperatives |
| Segments covered | Component, Route of Administration, Duration of Immunity, Disease Type, Type, Region |
| Country scope |
|
| Companies Included | Zoetis, Inc., Elanco Animal Health, Inc., Merck & Co., Inc., Boehringer Ingelheim International GmbH, Covetrus, Inc. (Clayton, Dubilier & Rice, LLC), Virbac, Heska Corporation (Antech Diagnostics, Inc), Ceva Sante Animale. Bioveta, a.s. |
By Component
By Route of Administration
By Duration of Immunity
By Disease Type
By Type
By Geography
This Market size is expected to reach $2.5 billion by 2031.
Rising Number of Households Adopting Cats as Pets are driving the Market in coming years, however, Lack Of Awareness and Education restraints the growth of the Market.
Zoetis, Inc., Elanco Animal Health, Inc., Merck & Co., Inc., Boehringer Ingelheim International GmbH, Covetrus, Inc. (Clayton, Dubilier & Rice, LLC), Virbac, Heska Corporation (Antech Diagnostics, Inc), Ceva Sante Animale. Bioveta, a.s.
The expected CAGR of this Market is 9.2% from 2024 to 2031.
The Injectables segment is generating the highest revenue in the Market by Route of Administration in 2023; thereby, achieving a market value of $1.8 billion by 2031.
The North America region dominated the Market by Region in 2023; thereby, achieving a market value of $888.4 million by 2031.
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 